| Bioactivity | LSD1/HDAC6-IN-2 (JBI-802) is an orally active dual inhibitor of LSD1-HDAC6, with IC50 values of 0.05 μM and 0.011 μM, respectively. LSD1/HDAC6-IN-2 (JBI-802) can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226, with EC50 values of 2 nM, 6 nM, and 280 nM, respectively. LSD1/HDAC6-IN-2 (JBI-802) can be used for research on diseases such as acute myeloid leukemia and lymphoma[1][2]. |
| Target | IC50: 0.05 μM, 0.011 μM (LSD1, HDAC6) |
| Invitro | LSD1/HDAC6-IN-2 (JBI-802) 对多发性骨髓瘤细胞 MM.1S、MM.1R 和 RPMI-8226 具有生长抑制活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> LSD1/HDAC6-IN-2 相关抗体: |
| In Vivo | LSD1/HDAC6-IN-2 (JBI-802) (25 mg/kg; 每天 1 次; 12 天; 口服) 在多发性骨髓瘤小鼠中具有抗肿瘤活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 2982787-50-6 |
| Formula | C21H23BrN4O2 |
| Molar Mass | 443.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yang X. Research progress of LSD1-based dual-target agents for cancer therapy. Bioorg Med Chem. 2024 Mar 1;101:117651. [2]. Sivanandhan D, et al. JBI-802, novel dual inhibitor of LSD1-HDAC6 for treatment of cancer[J]. Cancer Research, 2020, 80(16_Supplement): 1756-1756. |
LSD1/HDAC6-IN-2
CAS: 2982787-50-6 F: C21H23BrN4O2 W: 443.34
LSD1/HDAC6-IN-2 (JBI-802) is an orally active dual inhibitor of LSD1-HDAC6, with IC50 values of 0.05 μM and 0.011 μM,
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.